The <scp>TNM</scp> system (version 7) is the most accurate staging system for the prediction of loss of life expectancy in differentiated thyroid cancer

Tanase, Karina; Thies, E.; Mäder, Uwe; Reiners, Christoph; Verburg, Frederik A.

doi:10.1111/cen.12765

Cited by 24 publications

(11 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared to the data we reported previously, the prognostic power of TNM 8, while not necessarily better than TNM version 6/7, is still higher than that of TNM 5 (PVE: 0.26) and prior as well as any other staging systems developed for DTC, which all performed worse than any iteration of the TNM system …”

Section: Resultscontrasting

confidence: 88%

“…Therefore, the aim of the current study was to assess the changes resulting from these changes and to subsequently determine whether TNM version 8 is an improvement compared to previous iterations of the TNM system with regard to oncological prognostic power. To provide an optimal comparison of the 8th edition of the TNM system, we will do so using the same data set used for our previous comparison of nine different staging systems for DTC …”

Section: Introductionmentioning

confidence: 99%

“…To provide an optimal comparison of the 8th edition of the TNM system, we will do so using the same data set used for our previous comparison of nine different staging systems for DTC. 20…”

mentioning

confidence: 99%

See 2 more Smart Citations

The effects of the Union for International Cancer Control/American Joint Committee on Cancer Tumour, Node, Metastasis system version 8 on staging of differentiated thyroid cancer: a comparison to version 7

Verburg

Mäder

Luster

et al. 2018

Clinical Endocrinology

Self Cite

View full text Add to dashboard Cite

Summary Objective To assess the changes resulting from the changes from UICC/AJCC TNM version 7 to version 8 and to subsequently determine whether TNM version 8 is an improvement compared to previous iterations of the TNM system and other staging systems for differentiated thyroid cancer (DTC) with regard to prognostic power. Design Database study of DTC patients treated in our centre between 1978 up to and including 1 July 2014. Results were compared to our previous comparison of prognostic systems using the same data set. Patients 2257 DTC patients. Measurements Staging in accordance with TNM 7 and TNM 8. Thyroid cancer‐specific mortality; comparison was based on p‐values of univariate Cox regression analyses as well as analysis of the proportion of variance explained (PVE). Results There is a redistribution from stage 3 to lower stages affecting 206 (9.1%) patients. DTC‐related mortality according to Kaplan‐Meier for younger and older patients in TNM 7 had a slightly lower prognostic power than that in accordance with TNM 8 (P = 8.0 10−16 and P = 1.5 10−21, respectively). Overall staging is lower in 627/2257 (27.8%) patients. PVE (TNM 7: 0.29; TNM 8: 0.28) and the P‐value of Cox regressions (TNM 7: P = 7.1*10−52; TNM 8: P = 3.9*10−49) for TNM version 8 are marginally lower than that for TNM version 7, but still better than for any other DTC staging system. Conclusion TNM 8 results in a marked downstaging of patients compared to TNM 7. Although some changes, like the change in age boundary, appear to be associated with an improvement in prognostic power, the overall effect of the changes does not improve the predictive power compared to TNM 7.

show abstract

Section: Resultscontrasting

confidence: 88%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The effects of the Union for International Cancer Control/American Joint Committee on Cancer Tumour, Node, Metastasis system version 8 on staging of differentiated thyroid cancer: a comparison to version 7

Verburg

Mäder

Luster

et al. 2018

Clinical Endocrinology

Self Cite

View full text Add to dashboard Cite

show abstract

“… 1 – 3 In fact, to predict the clinical outcome of PTC, most clinicians utilize the international American Joint Committee on Cancer (AJCC) tumor, node, metastases (TNM) staging system, but this classical classification system cannot precisely predict nodal recurrence of patients with PTC, as this system was designed to predict patient mortality. 4 – 6 …”

Section: Introductionmentioning

confidence: 99%

Optimal Cut-Off Values of Lymph Node Ratio Predicting Recurrence in Papillary Thyroid Cancer

Lee

Choi

et al. 2016

Medicine

View full text Add to dashboard Cite

show abstract

“…Ductal and lobular carcinomas are the two most common histologic types of invasive breast cancer [12]. In addition, breast cancer can be classified via different commonly-used methods, including staging the tumor through the TNM system [13] [14], and grading the tumor through the Nottingham grading system, or the Scarf-Bloom-Richardson system [15] [16]. To reduce mortality rates and improve the patients' prognosis, early detection in association with staging or grading the tumor is used [17].…”

Section: Introductionmentioning

confidence: 99%

How Does the Cortactin Gene Expression Affect Breast Cancer among Iranian Females?

Tutunchi¹,

Saffari²,

Mazaheri³

et al. 2016

ABCR

View full text Add to dashboard Cite

Introduction: Breast cancer is the most common cancer in the Iranian female population, and the incidence of the disease is rising. Early detection in association with staging or grading the tumor is the most effective method to increase survival rates. Studies have revealed that cortactin overexpression may play a role in the final stages of tumor progression and affects invasion and cellular motility. The aim of this study is to evaluate cortactin gene expression among Iranian female patients with breast cancer. Materials and Methods: Samples belonging to 70 breast cancer patients were randomly selected from the Imam Khomeini tumor bank. Normal and tumor tissues were prepared and stored at −80˚C. Cortactin gene expression was evaluated by real-time PCR. Finally the data, along with demographic and clinical parameters, were analyzed using Prism 5.0 software, followed by t-test and ANOVA analysis. Results: Cortactin gene expression among tumor tissues increased 95.71% in comparison with normal tissues. A significant correlation between cortactin gene expression and lymph nodes' involvement (P = 0.0077) and tumor stage (P = 0.0030) was observed. However, tumor grade (P = 0.8598), tumor size (P = 0.3058), and patient's age (P = 0.4135) had no significant correlation with the gene's expression level. Discussion: This study demonstrated that the cortactin gene's overexpression in breast cancer may enhance lymph nodes' involvement. This study also found that the gene's expression was raised significantly in progressed stages of the cancer. Therefore, cortactin gene overexpression is an important factor indicating breast cells' invasion. Conclusion: The cortactin gene's expression level can be considered an accurate indicator for female breast cancer and also an appropriate biomarker for this cancer in clinical evaluations.

show abstract

The TNM system (version 7) is the most accurate staging system for the prediction of loss of life expectancy in differentiated thyroid cancer

Abstract: The UICC/AJCC TNM system version 7 outperforms other prognostic classification systems based on extent of disease at the start of treatment both for prediction of differentiated thyroid cancer-related death and for prediction of loss life expectancy.

Cited by 24 publications

References 33 publications

The effects of the Union for International Cancer Control/American Joint Committee on Cancer Tumour, Node, Metastasis system version 8 on staging of differentiated thyroid cancer: a comparison to version 7

The effects of the Union for International Cancer Control/American Joint Committee on Cancer Tumour, Node, Metastasis system version 8 on staging of differentiated thyroid cancer: a comparison to version 7

Optimal Cut-Off Values of Lymph Node Ratio Predicting Recurrence in Papillary Thyroid Cancer

How Does the Cortactin Gene Expression Affect Breast Cancer among Iranian Females?

Contact Info

Product

Resources

About